Saturday 17 October 2026 Export ENLV’s income statement to Excel — free account

Enlivex Ltd.

In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.21 0.01 −4.55%

Follow ENLV

Alert me

Market cap: $4.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 87.43%

Capital & Financial Ratios $m

Market Cap 4.46

Revenue —

Net Income 1,235.53

Free Cash Flow (10.48)

Net Debt (3,730.33)

Current Ratio 119.39

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 42.24%

Next Y EPS Growth (29.85%)

Next Y revenue growth —

Next 5Y EPS Growth 72.14%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	27	23	1,739	3,748
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	34	26	1,743	3,751

	2023	2024	2025	Q'26
Payables	1	1	4	2
ST’ Debt	—	—	—	17
Other	—	—	—	0
	6	4	9	31

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	59.70%	122.49%	224.09%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(5)	(1)	(2)	(3)	(10)
’24	(5)	(2)	(3)	(4)	(13)
’23	(6)	(7)	(5)	(5)	(24)
’22	(3)	(9)	(7)	(5)	(24)
’21	(2)	(4)	(4)	(7)	(18)
’20	1	(4)	(2)	(6)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(5)	(1)	(2)	(3)	(10)
’24	(4)	(2)	(3)	(4)	(13)
’23	(6)	(7)	(5)	(5)	(24)
’22	(4)	(13)	(8)	(7)	(32)
’21	(3)	(5)	(4)	(8)	(19)
’20	1	(4)	(3)	(6)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	97.84	—	—	—
’25	(2.25)	(1.20)	(1.35)	386.67	382.01
’24	(3.30)	(2.40)	(1.80)	(3.45)	(10.94)
’23	(5.85)	(5.55)	(4.80)	(7.20)	(23.39)
’22	(6.75)	(8.10)	(4.65)	(5.85)	(25.34)
’21	(2.85)	(2.55)	(2.85)	(3.90)	(12.14)
’20	(1.05)	(3.45)	(2.40)	(6.45)	(13.49)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	552.00	178.80	92.88	93.75	53.85	84.45	54.30	18.00	12.15	9.90	Analyst estimates 2026–2028 Powerpack
	High	4,770.00	930.00	718.80	673.50	254.10	441.00	129.60	69.75	68.85	31.50
People
People	Employees	12	2	31	37	51	72	78	50	36	34
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(16)	(3)	(4)	(9)	(12)	(14)	(31)	(29)	(15)	1,618
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(16)	(3)	(4)	(9)	(12)	(14)	(31)	(29)	(15)	1,236
	Depreciation	0	0	0	0	0	1	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(605.70)	(214.69)	(20.99)	(16.79)	(13.49)	(12.14)	(25.34)	(23.39)	(10.94)	405.40
	Cash flow	(582.18)	(10.08)	(13.50)	(12.20)	(12.53)	(14.73)	(19.52)	(18.99)	(9.51)	(3.42)
	Capex	(0.68)	(0.57)	(1.97)	(0.33)	(1.16)	(1.36)	(6.62)	(0.08)	0.06	(0.02)
	Free cash flow	(582.86)	(10.65)	(15.47)	(12.53)	(13.69)	(16.09)	(26.14)	(19.07)	(9.45)	(3.44)
	Book value	327.03	37.17	41.46	19.56	40.40	71.38	46.33	24.28	17.24	634.85
	Shares, m	0	0	0	1	1	1	1	1	1	3
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(15)	(2)	(3)	(7)	(11)	(18)	(24)	(24)	(13)	(10)
	Capex	0	0	0	0	(1)	(2)	(8)	0	0	0
	Free cash flow	(16)	(2)	(4)	(7)	(12)	(19)	(32)	(24)	(13)	(10)
Balance, $m
Balance, $m	Working capital	9	8	9	10	34	82	46	28	22	1,734
	Total debt	—	—	—	0	0	5	4	—	0	0
	Net debt	(10)	(9)	(10)	(13)	(36)	(79)	(46)	(27)	(23)	(1,738)
	Shareholders’ equity	9	8	10	11	35	85	57	30	24	1,935
Returns, %
Returns, %	ROA	(102.88)	(31.93)	(47.64)	(65.64)	(40.83)	(21.35)	(38.16)	(55.65)	(46.54)	104.94
	ROIC	0.00	0.00	0.00	0.00	0.00	(191.41)	(149.41)	(664.68)	(2,533.16)	(4.78)
	ROE	(120.33)	(38.50)	(56.96)	(91.71)	(50.56)	(24.01)	(43.78)	(66.88)	(55.95)	126.17

Negative figures in brackets.

All 10 years →

Fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LGVN Longeveron Inc.	$4.8M	— (loss-making)	— (loss-making)	−9.18% (below 0%: shrinking)	n/m	−49.12% (below 0%: shrinking)	63.41%	(2,150.17%)	Compare
XBIO Xenetic Biosciences, Inc.	$4.7M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)	Compare
PCSA Heatwurx Inc.	$4.7M	1.6×	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
DRMA Dermata Therapeutics, Inc.	$4.5M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$4.5M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%
NCNA NuCana PLC Sponsored ADR	$4.4M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.3M	1.0×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
LIMN Liminatus Pharma Inc.	$4.3M	— (loss-making)	—	—	n/m	+89.00% (above 0%: growing)	—	0.00%	Compare
Median of peers	$4.5M	—	—	−9.18%	—	+15.14%	23.77%	0.00%

All 614 Biotechnology stocks →

Enlivex Ltd. (ENLV) key facts

Enlivex Ltd. (ENLV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ENLV traded at $0.21, a market capitalization of $4.5 million.
Return on equity was 126.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.